PharmaCyte Biotech commences pilot phase of pig study to address FDA clinical hold for pancreatic cancer trial

PharmaCyte Biotech, Inc.

Pilot study in two Yorkshire pigs evaluates microcatheter delivery of CypCaps into pancreatic arterial system.
Data will finalize full-scale 90-pig study protocol; results to be presented to FDA in Type A meeting.
Study aims to lift clinical hold on planned Phase 2b trial for locally advanced inoperable pancreatic cancer (LAPC).
CypCaps contain radiopaque microspheres to track movement via imaging and histology over one-week observation.
Study conducted by CBSET, Inc. in Lexington, MA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.